PAF1 antibody (ab52720)

Product Name 

PAF1 antibody

Product type 

Primary antibodies

Description 

Mouse polyclonal to PAF1

Immunogen 

Recombinant fusion protein: RDKLRMKFDP INFATVDEED DEDEEQPEDV KKESEGDSKT EGSEQEGENE KDEEIKQEKE NEQDEENKQD ENRAADTPET SDAVHTEQKP EEEKETLQEE , corresponding to amino acids 346-445 of Saccharomyces cerevisiae PAF1
BLAST 'RDKLRMKFDP INFATVDEED DEDEEQPEDV KKESEGDSKT EGSEQEGENE KDEEIKQEKE NEQDEENKQD ENRAADTPET SDAVHTEQKP EEEKETLQEE ' with or

Reacts with 
(species key)

Sc

Specificity 

This antibody reacts with PAF1.

Tested applications 
(see key)

WB

Abreviews 

Customer reviews (see key)

Read about Abreviews

Application notes 
(see key)

Recommended dilutions
WB: 1/1000. Predicted molecular weight: 60 kDa.
This antibody has been tested in Western blot against an E.coli lysate containing the partial recombinant fusion protein used as an immunogen. We have no data on detection of endogenous protein.

Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.

Cellular localization 

Nuclear

Research areas 

Chromatin and Nuclear Signaling >> Transcription >> Elongation factors
Chromatin and Nuclear Signaling >> Transcription >> Cancer susceptibility >> Proto-oncogenes
Chromatin and Nuclear Signaling >> Transcription >> Polymerase associated factors >> Pol II Transcription >> Polymerase

Relevance 

In yeast, PAF1 acts as a docking protein and is involved in transcriptional elongation through interactions with RNA polymerase II and other members of the transcription machinery. The human homolog has also been shown to interact with RNA polymerase II, in particular with the form which is phosphorylated on Serine 2 or 5 in the carboxy-terminal domain (CTD). It also associates with HRPT2 (parafibromin) and other members of the PAF1 complex (LEO1 and CTR9). This complex is involved in transcriptional elongation and 3' end processing. There is evidence that overexpression of PAF1 is involved in cancer development.

This antibody was raised by a genetic immunization technique. Genetic immunization can be used to generate antibodies by directly delivering antigen-coding DNA into the animal, rather than injecting a protein or peptide (Tang et al. PubMed: 1545867; Chambers and Johnston PubMed 12910245; Barry and Johnston PubMed: 9234514). The animal's cells produce the protein, which stimulates the animal's immune system to produce antibodies against that particular protein.

A vector coding for a partial fusion protein was used for genetic immunisation of a mouse and the resulting serum was tested in Western blot against an E.coli lysate containing that partial fusion protein.

Genetic immunization offers enormous advantages over the traditional protein-based immunization method. DNA is faster, cheaper and easier to produce and can be produced by standard techniques readily amenable to automation. Furthermore, the antibodies generated by genetic immunization are usually of superior quality with regard to specificity, affinity and recognizing the native protein.

Raised in 

Mouse

Clonality 

Polyclonal

Isotype 

IgG

Purity 

Whole antiserum

Storage buffer 

Preservative: None
Constituents: 50% Glycerol, Whole serum

Material safety datasheet (MSDS) for this product:
Glycerol MSDS

Form 

Liquid

Concentration 

Concentration not determined - why is this?

Storage instructions 

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

See below for PAF1 antibody images, references, products related to ab52720 and other tools.

PAF1 antibody images:

Customer reviews (feedback) regarding PAF1 antibody

Customer FAQs regarding PAF1 antibody

Protocols for PAF1 antibody

Price and availability of products related to PAF1 antibody

PAF1 antibody - related products: